Codex DNA Inc News - DNAY

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Codex DNA (DNAY) Receives a Rating Update from a Top Analyst

Jefferies analyst Brandon Couillard maintained a Buy rating on Codex DNA (DNAY – Research Report) today and set a price target of $10.00. The...

Codex DNA to Present at the 2022 Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop...

Codex DNA Showcases Automated Synthetic Biology Solutions for Accelerating Discovery Workflows at the Antibody Engineering and Therapeutics Europe Conference

BioXp™ system and RapidAMP™ cell-free DNA kit rapidly accelerate antibody discovery pipelines by addressing...

Current Report Filing (8-k)

0001850079false00018500792022-05-102022-05-10UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-KCURRENT REPORTPursuant...

Codex DNA Reports First Quarter 2022 Financial Results

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop...

Codex DNA to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop...

Proxy Statement (definitive) (def 14a)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_____________________________SCHEDULE 14APROXY STATEMENT PURSUANT TO SECTION...

Codex DNA Unveils Automated Synthetic Biology Solutions for Antibody and Protein Engineering of Biotherapeutic Targets at 18th Annual PEGS Boston Conference and Expo

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop...

Codex DNA Demonstrates End-to-End Workflow for Storing and Retrieving Data in Synthetic DNA

SAN DIEGO, April 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop...

Codex DNA Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development at World Vaccine Congress Washington 2022

SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop...

Codex DNA to Showcase Innovative SOLA Enzymatic DNA Synthesis Technology and Automated Benchtop BioXp System at SynBioBeta’s Built with Biology Global Conference

SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Codex DNA Inc (DNAY)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

DNAY News

Statement of Changes in Beneficial Ownership (4)

Codex DNA (DNAY) Receives a Rating Update from a Top Analyst

Codex DNA to Present at the 2022 Jefferies Healthcare Conference

Codex DNA Showcases Automated Synthetic Biology Solutions for Accelerating Discovery Workflows at the Antibody Engineering and Therapeutics Europe Conference

Current Report Filing (8-k)

Codex DNA Reports First Quarter 2022 Financial Results

Codex DNA to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

Proxy Statement (definitive) (def 14a)

Codex DNA Unveils Automated Synthetic Biology Solutions for Antibody and Protein Engineering of Biotherapeutic Targets at 18th Annual PEGS Boston Conference and Expo

Codex DNA Demonstrates End-to-End Workflow for Storing and Retrieving Data in Synthetic DNA

Codex DNA Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development at World Vaccine Congress Washington 2022

Codex DNA to Showcase Innovative SOLA Enzymatic DNA Synthesis Technology and Automated Benchtop BioXp System at SynBioBeta’s Built with Biology Global Conference

Analysts Offer Insights on Services Companies: Franklin Covey Company (FC) and Codex DNA (DNAY)

Securities Registration: Employee Benefit Plan (s-8)

Current Report Filing (8-k)

DNAY Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Codex DNA Inc (DNAY) News

Codex DNA Inc (DNAY)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

DNAY News

Statement of Changes in Beneficial Ownership (4)

Codex DNA (DNAY) Receives a Rating Update from a Top Analyst

Codex DNA to Present at the 2022 Jefferies Healthcare Conference

Codex DNA Showcases Automated Synthetic Biology Solutions for Accelerating Discovery Workflows at the Antibody Engineering and Therapeutics Europe Conference

Current Report Filing (8-k)

Codex DNA Reports First Quarter 2022 Financial Results

Codex DNA to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

Proxy Statement (definitive) (def 14a)

Codex DNA Unveils Automated Synthetic Biology Solutions for Antibody and Protein Engineering of Biotherapeutic Targets at 18th Annual PEGS Boston Conference and Expo

Codex DNA Demonstrates End-to-End Workflow for Storing and Retrieving Data in Synthetic DNA

Codex DNA Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development at World Vaccine Congress Washington 2022

Codex DNA to Showcase Innovative SOLA Enzymatic DNA Synthesis Technology and Automated Benchtop BioXp System at SynBioBeta’s Built with Biology Global Conference

Analysts Offer Insights on Services Companies: Franklin Covey Company (FC) and Codex DNA (DNAY)

Securities Registration: Employee Benefit Plan (s-8)

Current Report Filing (8-k)

DNAY Discussion

Your Recent History